Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

161.66 -1.25 (-0.77%)
Official Closing Price Updated: 4:10 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,550,526
Open 162.57
Bid (Size) 161.66 (9)
Ask (Size) 162.25 (3)
Prev. Close 162.91
Today's Range 161.59 - 163.50
52wk Range 150.11 - 181.04
Shares Outstanding 2,628,679,824
Dividend Yield 2.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Johnson & Johnson Unusual Options Activity
Via Benzinga

Performance

YTD
-9.28%
-9.28%
1 Month
-3.40%
-3.40%
3 Month
-1.35%
-1.35%
6 Month
+7.02%
+7.02%
1 Year
-2.01%
-2.01%

More News

Read More
2 Incredibly Cheap Dividend Stocks to Buy Now
Via The Motley Fool
Flee to Healthcare Stocks if Recession Rears its Head?
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
Via The Motley Fool
Better Buy: J&J vs. Kenvue
Via The Motley Fool
Johnson & Johnson Unusual Options Activity
Via Benzinga
3 No-Brainer Stocks to Buy With $500 Right Now
Via The Motley Fool
7 Safe and Steady Dividend Stocks to Buy for Volatile Time
Via InvestorPlace
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
Via FinancialNewsMedia
Topics Economy
Exposures Economy Product Safety
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
3 High-Quality Dividend Stocks Yielding 3%-Plus to Buy for Decades of Rising Income
Via The Motley Fool
3 Great Dividend Stocks You Can Buy for Less Than $50
Via The Motley Fool
Sandoz Pushes Product Launch Plans As Novartis Shareholders Approve The Spin-Off
Via Benzinga
The 3 Most Undervalued Dow Stocks to Buy in September 2023
Via InvestorPlace
Topics Stocks
Exposures US Equities
Lawsuit Against Dummy Pills For Allergy, Cold: Johnson & Johnson And Procter & Gamble Face Allegations
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Blue-Chip Stocks to Watch in the ‘Green Zone’
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity
From Johnson & Johnson
Via Business Wire
3 Warren Buffett Stocks That Are Near Their 52-Week Lows
Via The Motley Fool
Buy the Dip: 3 Healthcare Stocks to Snag Now for Supercharged Gains
Via InvestorPlace
Here's My Top Growth Stock to Buy in 2023
Via The Motley Fool
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
Via Benzinga
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
Via Benzinga
Exposures Product Safety
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.